167 related articles for article (PubMed ID: 38498998)
1. Discovery of Conformationally Constrained ALK2 Inhibitors.
González-Álvarez H; Ensan D; Xin T; Wong JF; Zepeda-Velázquez CA; Cros J; Sweeney MN; Hoffer L; Kiyota T; Wilson BJ; Aman A; Roberts O; Isaac MB; Bullock AN; Smil D; Al-Awar R
J Med Chem; 2024 Mar; 67(6):4707-4725. PubMed ID: 38498998
[TBL] [Abstract][Full Text] [Related]
2. Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma.
Smil D; Wong JF; Williams EP; Adamson RJ; Howarth A; McLeod DA; Mamai A; Kim S; Wilson BJ; Kiyota T; Aman A; Owen J; Poda G; Horiuchi KY; Kuznetsova E; Ma H; Hamblin JN; Cramp S; Roberts OG; Edwards AM; Uehling D; Al-Awar R; Bullock AN; O'Meara JA; Isaac MB
J Med Chem; 2020 Sep; 63(17):10061-10085. PubMed ID: 32787083
[TBL] [Abstract][Full Text] [Related]
3. Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.
Ensan D; Smil D; Zepeda-Velázquez CA; Panagopoulos D; Wong JF; Williams EP; Adamson R; Bullock AN; Kiyota T; Aman A; Roberts OG; Edwards AM; O'Meara JA; Isaac MB; Al-Awar R
J Med Chem; 2020 May; 63(9):4978-4996. PubMed ID: 32369358
[TBL] [Abstract][Full Text] [Related]
4. ALK2 inhibitors display beneficial effects in preclinical models of
Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C
Commun Biol; 2019; 2():156. PubMed ID: 31098401
[TBL] [Abstract][Full Text] [Related]
5. ALK2: A Therapeutic Target for Fibrodysplasia Ossificans Progressiva and Diffuse Intrinsic Pontine Glioma.
Sekimata K; Sato T; Sakai N
Chem Pharm Bull (Tokyo); 2020; 68(3):194-200. PubMed ID: 32115526
[TBL] [Abstract][Full Text] [Related]
6. Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of
Murrell E; Tong J; Smil D; Kiyota T; Aman AM; Isaac MB; Watson IDG; Vasdev N
ACS Med Chem Lett; 2021 May; 12(5):846-850. PubMed ID: 34055235
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2.
Nguyen MH; Atasoylu O; Wu L; Kapilashrami K; Pusey M; Gallagher K; Lai CT; Zhao P; Barbosa J; Liu K; He C; Zhang C; Styduhar ED; Witten MR; Chen Y; Lin L; Yang YO; Covington M; Diamond S; Yeleswaram S; Yao W
ACS Med Chem Lett; 2022 Jul; 13(7):1159-1164. PubMed ID: 35859885
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in ALK2 Inhibitors.
Rooney L; Jones C
ACS Omega; 2021 Aug; 6(32):20729-20734. PubMed ID: 34423181
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Mohedas AH; Wang Y; Sanvitale CE; Canning P; Choi S; Xing X; Bullock AN; Cuny GD; Yu PB
J Med Chem; 2014 Oct; 57(19):7900-15. PubMed ID: 25101911
[TBL] [Abstract][Full Text] [Related]
10. Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
Machiya A; Tsukamoto S; Ohte S; Kuratani M; Fujimoto M; Kumagai K; Osawa K; Suda N; Bullock AN; Katagiri T
Bone; 2018 Jun; 111():101-108. PubMed ID: 29551750
[TBL] [Abstract][Full Text] [Related]
11. Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors.
Engers DW; Bollinger SR; Felts AS; Vadukoot AK; Williams CH; Blobaum AL; Lindsley CW; Hong CC; Hopkins CR
Bioorg Med Chem Lett; 2020 Sep; 30(18):127418. PubMed ID: 32750526
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
13. ALK2 Receptor Kinase Association with FKBP12.6 Is Structurally Conserved with the ALK2-FKBP12 Complex.
Williams E; Riesebos E; Kerr G; Bullock AN
Biomedicines; 2021 Jan; 9(2):. PubMed ID: 33572801
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma.
Tsoli M; Liu J; Franshaw L; Shen H; Cheng C; Jung M; Joshi S; Ehteda A; Khan A; Montero-Carcabosso A; Dilda PJ; Hogg P; Ziegler DS
Oncotarget; 2018 Jan; 9(7):7541-7556. PubMed ID: 29484131
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-Loaded Gold Nanoarchitectures as a Therapeutic Strategy against Diffuse Intrinsic Pontine Glioma.
Ung C; Tsoli M; Liu J; Cassano D; Pocoví-Martínez S; Upton DH; Ehteda A; Mansfeld FM; Failes TW; Farfalla A; Katsinas C; Kavallaris M; Arndt GM; Vittorio O; Cirillo G; Voliani V; Ziegler DS
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33805713
[TBL] [Abstract][Full Text] [Related]
16. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma.
Zhao G; Newbury P; Ishi Y; Chekalin E; Zeng B; Glicksberg BS; Wen A; Paithankar S; Sasaki T; Suri A; Nazarian J; Pacold ME; Brat DJ; Nicolaides T; Chen B; Hashizume R
Acta Neuropathol Commun; 2022 Oct; 10(1):150. PubMed ID: 36274161
[TBL] [Abstract][Full Text] [Related]
17. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
Deligne C; Hachani J; Duban-Deweer S; Meignan S; Leblond P; Carcaboso AM; Sano Y; Shimizu F; Kanda T; Gosselet F; Dehouck MP; Mysiorek C
Fluids Barriers CNS; 2020 Jun; 17(1):37. PubMed ID: 32487241
[TBL] [Abstract][Full Text] [Related]
18. Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.
Pacifici M; Shore EM
Cytokine Growth Factor Rev; 2016 Feb; 27():93-104. PubMed ID: 26776312
[TBL] [Abstract][Full Text] [Related]
19. Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches.
Sato T; Sekimata K; Sakai N; Watanabe H; Mishima-Tsumagari C; Taguri T; Matsumoto T; Fujii Y; Handa N; Tanaka A; Shirouzu M; Yokoyama S; Hashizume Y; Miyazono K; Koyama H; Honma T
ACS Omega; 2020 May; 5(20):11411-11423. PubMed ID: 32478230
[TBL] [Abstract][Full Text] [Related]
20. Heteroaromatic Inhibitors of the Astacin Proteinases Meprin α, Meprin β and Ovastacin Discovered by a Scaffold-Hopping Approach.
Tan K; Jäger C; Körschgen H; Geissler S; Schlenzig D; Buchholz M; Stöcker W; Ramsbeck D
ChemMedChem; 2021 Mar; 16(6):976-988. PubMed ID: 33369214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
